{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:49:06Z","timestamp":1740138546511,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12012-018-9494-7","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T05:18:52Z","timestamp":1543900732000},"page":"237-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Digitalis Promotes Ventricular Arrhythmias in Flecainide- and Ranolazine-Pretreated Hearts"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9172-296X","authenticated-orcid":false,"given":"Christian","family":"Ellermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Wolfes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Puckhaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"B\u00f6geholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Leitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp S.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit","family":"Frommeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"issue":"11","key":"9494_CR1","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/europace\/euw295","volume":"18","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., et al. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 18(11), 1609\u20131678.","journal-title":"Europace"},{"issue":"6","key":"9494_CR2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1161\/CIRCEP.111.964908","volume":"4","author":"LA Gonano","year":"2011","unstructured":"Gonano, L. A., Sep\u00falveda, M., Rico, Y., Kaetzel, M., Valverde, C. A., Dedman, J., et al. (2011). Calcium-Calmodulin Kinase II mediates digitalis-induced arrhythmias. Circulation Arrhythmia Electrophysiology, 4(6), 947\u2013957.","journal-title":"Circulation Arrhythmia Electrophysiology"},{"issue":"7","key":"9494_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.tcm.2016.03.011","volume":"26","author":"OJ Ziff","year":"2016","unstructured":"Ziff, O. J., Kotecha, D.. Digoxin (2016). The good and the bad. Trends in Cardiovascular Medicine, 26(7), 585\u2013595.","journal-title":"Trends in Cardiovascular Medicine"},{"issue":"27","key":"9494_CR4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Coats, A. J., et al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37(27), 2129\u20132200.","journal-title":"European Heart Journal"},{"issue":"7","key":"9494_CR5","doi-asserted-by":"publisher","first-page":"e006035","DOI":"10.1161\/JAHA.117.006035","volume":"6","author":"A Eisen","year":"2017","unstructured":"Eisen, A., Ruff, C. T., Braunwald, E., Hamershock, R. A., Lewis, B. S., Hassager, C., et al. (2017). Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 trial. Journal of the American Heart Association, 6(7), e006035.","journal-title":"Journal of the American Heart Association"},{"issue":"9985","key":"9494_CR6","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/S0140-6736(14)61836-5","volume":"385","author":"JB Washam","year":"2015","unstructured":"Washam, J. B., Stevens, S. R., Lokhnygina, Y., Halperin, J. L., Breithardt, G., Singer, D. E., et al. (2015). Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). The Lancet, 385(9985), 2363\u20132370.","journal-title":"The Lancet"},{"issue":"28","key":"9494_CR7","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/eurheartj\/ehv143","volume":"36","author":"M Vamos","year":"2015","unstructured":"Vamos, M., Erath, J. W., & Hohnloser, S. H. (2015). Digoxin-associated mortality: A systematic review and meta-analysis of the literature. European Heart Journal, 36(28), 1831\u20131838.","journal-title":"European Heart Journal"},{"issue":"10","key":"9494_CR8","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jacc.2017.12.060","volume":"71","author":"RD Lopes","year":"2018","unstructured":"Lopes, R. D., Rordorf, R., De Ferrari, G. M., Leonardi, S., Thomas, L., Wojdyla, D. M., et al. (2018). Digoxin and mortality in patients with atrial fibrillation. Journal of the American College of Cardiology, 71(10), 1063\u20131074.","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"9494_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00380-003-0731-y","volume":"19","author":"A Takahara","year":"2004","unstructured":"Takahara, A., Sugiyama, A., & Hashimoto, K. (2004). Effects of class I antiarrhythmic drugs on the digitalis-induced triggered activity arrhythmia model: A rationale for the short-term use of class I drugs against triggered arrhythmias. Heart and Vessels, 19(1), 43\u201348.","journal-title":"Heart and Vessels"},{"issue":"6","key":"9494_CR10","first-page":"1019","volume":"7","author":"SH Hohnloser","year":"2014","unstructured":"Hohnloser, S. H., Halperin, J. L., Camm, A. J., Gao, P., Radzik, D., & Connolly, S. J. Interaction between digoxin and dronedarone in the PALLAS trial. Circulation: Arrhythmia and Electrophysiology. 2014:7(6), 1019.","journal-title":"Circulation: Arrhythmia and Electrophysiology"},{"issue":"8","key":"9494_CR11","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1093\/europace\/euu393","volume":"17","author":"G Frommeyer","year":"2015","unstructured":"Frommeyer, G., Milberg, P., Schulze Grotthoff, J., Dechering, D. G., Kochh\u00e4user, S., Stypmann, J., et al. (2015). Dronedarone and digitalis: Individually reduced post-repolarization refractoriness enhances life-threatening arrhythmias. Europace, 17(8), 1300\u20131308.","journal-title":"Europace"},{"key":"9494_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijcard.2016.11.024","volume":"228","author":"G Frommeyer","year":"2017","unstructured":"Frommeyer, G., Puckhaber, D., Ellermann, C., Dechering, D. G., Kochh\u00e4user, S., Leitz, P., et al. (2017). Interactions of digitalis and class-III antiarrhythmic drugs: Amiodarone versus dronedarone. International Journal of Cardiology, 228, 74\u201379.","journal-title":"International Journal of Cardiology"},{"issue":"6","key":"9494_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/bcpt.12829","volume":"121","author":"G Frommeyer","year":"2017","unstructured":"Frommeyer, G., Weller, J., Ellermann, C., B\u00f6geholz, N., Leitz, P., Dechering, D. G., et al. (2017). Ivabradine reduces digitalis-induced ventricular arrhythmias. Basic & Clinical Pharmacology & Toxicology, 121(6), 526\u2013530.","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"3","key":"9494_CR14","doi-asserted-by":"publisher","first-page":"e003196","DOI":"10.1161\/JAHA.116.003196","volume":"5","author":"E Rayner-Hartley","year":"2016","unstructured":"Rayner-Hartley, E., & Sedlak, T. (2016). Ranolazine: A contemporary review. Journal of the American Heart Association, 5(3), e003196.","journal-title":"Journal of the American Heart Association"},{"key":"9494_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijcard.2015.03.324","volume":"187","author":"T Gupta","year":"2015","unstructured":"Gupta, T., Khera, S., Kolte, D., Aronow, W. S., & Iwai, S. (2015). Antiarrhythmic properties of ranolazine: A review of the current evidence. International Journal of Cardiology, 187, 66\u201374.","journal-title":"International Journal of Cardiology"},{"issue":"38","key":"9494_CR16","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., et al. (2013). 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal, 34(38), 2949\u20133003.","journal-title":"European Heart Journal"},{"key":"9494_CR17","doi-asserted-by":"crossref","unstructured":"Reiffel, J. A., Camm, A. J., Belardinelli, L., Zeng, D., Karwatowska-Prokopczuk, E., Olmsted, A., et al. The HARMONY trial: Combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism. Circulation: Arrhythmia and Electrophysiology. 2015:CIRCEP. 115.002856..","DOI":"10.1161\/CIRCEP.115.002856"},{"issue":"12","key":"9494_CR18","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1111\/j.1540-8159.2011.03208.x","volume":"34","author":"TJ Bunch","year":"2011","unstructured":"Bunch, T. J., Mahapatra, S., Murdock, D., Molden, J., Weiss, J. P., May, H. T., et al. (2011). Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing and Clinical Electrophysiology, 34(12), 1600\u20131606.","journal-title":"Pacing and Clinical Electrophysiology"},{"issue":"6","key":"9494_CR19","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1111\/1755-5922.12035","volume":"31","author":"G Frommeyer","year":"2013","unstructured":"Frommeyer, G., Milberg, P., Uphaus, T., Kaiser, D., Kaese, S., Breithardt, G., et al. (2013). Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation. Cardiovascular Therapeutics, 31(6), e63\u2013e71. \n                    https:\/\/doi.org\/10.1111\/1755-5922.12035\n                    \n                  .","journal-title":"Cardiovascular Therapeutics"},{"issue":"10","key":"9494_CR20","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/jce.13029","volume":"27","author":"G Frommeyer","year":"2016","unstructured":"Frommeyer, G., Ellermann, C., Dechering, D. G., Kochh\u00e4user, S., B\u00f6geholz, N., G\u00fcner, F., et al. (2016). Ranolazine and vernakalant prevent ventricular arrhythmias in an experimental whole-heart model of short QT syndrome. Journal of Cardiovascular Electrophysiology, 27(10), 1214\u20131219.","journal-title":"Journal of Cardiovascular Electrophysiology"},{"key":"9494_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ijcard.2017.06.005","volume":"243","author":"C Ellermann","year":"2017","unstructured":"Ellermann, C., Wolfes, J., Kochh\u00e4user, S., Dechering, D. G., Reinke, F., Wasmer, K., et al. (2017). Divergent antiarrhythmic effects of resveratrol and piceatannol in a whole-heart model of long QT syndrome. International Journal of Cardiology, 243, 233\u2013238.","journal-title":"International Journal of Cardiology"},{"issue":"2","key":"9494_CR22","doi-asserted-by":"publisher","first-page":"e12244","DOI":"10.1111\/1755-5922.12244","volume":"35","author":"G Frommeyer","year":"2017","unstructured":"Frommeyer, G., Sterneberg, M., Dechering, D. G., Kaese, S., B\u00f6geholz, N., Pott, C., et al. (2017). Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent. Cardiovascular Therapeutics, 35(2), e12244.","journal-title":"Cardiovascular Therapeutics"},{"issue":"12","key":"9494_CR23","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.hrthm.2012.08.029","volume":"9","author":"G Frommeyer","year":"2012","unstructured":"Frommeyer, G., Kaiser, D., Uphaus, T., Kaese, S., Osada, N., Rajamani, S., et al. (2012). Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits. Heart Rhythm, 9(12), 2051\u20132058.","journal-title":"Heart Rhythm"},{"issue":"3","key":"9494_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/FJC.0b013e3181ce5e14","volume":"55","author":"EE Morgan","year":"2010","unstructured":"Morgan, E. E., Li, Z., Stebal, C., Belliard, A., Tennyson, G., Salari, B., et al. (2010). Preconditioning by sub-inotropic doses of ouabain in the Langendorff-perfused rabbit heart. Journal of Cardiovascular Pharmacology, 55(3), 234.","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"10","key":"9494_CR25","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/europace\/eux383","volume":"20","author":"C Ellermann","year":"2018","unstructured":"Ellermann, C., Sterneberg, M., Kochh\u00e4user, S., Dechering, D. G., Fehr, M., Eckardt, L., et al. (2018). Antiarrhythmic effect of antazoline in experimental models of acquired short-and long-QT-syndromes. Europace, 20(10), 1699\u20131706.","journal-title":"Europace"},{"issue":"5","key":"9494_CR26","doi-asserted-by":"publisher","first-page":"B52","DOI":"10.1016\/0002-9149(84)90502-2","volume":"53","author":"GP Lewis","year":"1984","unstructured":"Lewis, G. P., & Holtzman, J. L. (1984). Interaction of flecainide with digoxin and propranolol. American Journal of Cardiology, 53(5), B52\u2013B57.","journal-title":"American Journal of Cardiology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-018-9494-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-018-9494-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-018-9494-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T19:23:40Z","timestamp":1575401020000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-018-9494-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,4]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["9494"],"URL":"https:\/\/doi.org\/10.1007\/s12012-018-9494-7","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"type":"print","value":"1530-7905"},{"type":"electronic","value":"1559-0259"}],"subject":[],"published":{"date-parts":[[2018,12,4]]},"assertion":[{"value":"4 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All other authors declare to have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national and institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval<!--Emphasis Type='Bold' removed-->and Statement"}}]}}